to the 2023 Investors up to an aggregate of approximately $50,000,000 of securities of the Company in a private placement of units (each, a “2023 Unit”). Each 2023 Unit consisted of one Common Share and one warrant exercisable for one Common Share. Pursuant to the 2023 Subscription Agreements, the Company agreed to issue to the 2023 Investors 22,929,468 2023 Units for aggregate gross proceeds of approximately $25,000,000. In addition, the Company granted the 2023 Investors an over-allotment option to purchase up to an additional 22,929,468 2023 Units for aggregate proceeds of up to approximately $25,000,000, which was exercisable at the option of the 2023 Investors within 45 days of the date of the 2023 Subscription Agreement. The over-allotment option was not exercised. The purchase price per 2023 Unit was $1.09. The 2023 Units were issued to the 2023 Investors in reliance on the exemption from securities registration in Section 4(a)(2) under the Securities Act.
•
On August 29, 2023, the Company issued 15,206,046 Common Shares to Les Serres Stéphane Bertrand Inc. (“LSB”) pursuant to the amended and restated share purchase agreement, dated as of August 29, 2023, by and among the Company, LSB and Les Serres Vert Cannabis Inc. The Common Shares were issued in reliance on the exemption from securities registration in Section 4(a)(2) under the Securities Act.
•
On July 13, 2023, the Company entered into separate, privately negotiated redemption agreements (collectively, the “Redemption Agreements”) with certain holders (the “July 2023 Noteholders”) of the Company’s 4.25% senior notes due 2023 (the “Notes”) to redeem (collectively, the “Redemptions”) C$192,511,000 aggregate principal amount of Notes for consideration consisting of: (i) cash, including accrued and unpaid interest owing under such Notes, (ii) an aggregate 90,430,920 Common Shares (the “Redemption Shares”) at a deemed price of $0.57 per Redemption Share; and (iii) C$40,380,000 aggregate principal amount of unsecured non-interest bearing convertible debentures (the “Redemption Debentures”), which are convertible into Common Shares at a conversion price of $0.55 per Redemption Debenture. In connection with the Redemptions, an aggregate of 90,196,657 Redemption Shares were issued to the July 2023 Noteholders on July 14, 2023 and an aggregate of 234,263 Redemption Shares were issued on July 17, 2023 in partial satisfaction of the purchase price payable to the July 2023 Noteholders in accordance with the Redemption Agreements. The Redemptions were conducted as private placements, and the Redemption Shares were issued in reliance on the exemption from securities registration in Section 4(a)(2) under the Securities Act.
•
On June 29, 2023, the Company entered into separate, privately negotiated exchange agreements with a limited number of holders (the “June 2023 Noteholders”) of the Company’s 4.25% senior notes due 2023 (the “Notes”) to exchange (collectively, the “June 2023 Exchanges”) C$12.5 million principal amount of Notes for consideration consisting of cash, including accrued and unpaid interest owing under such Notes, and a number of Common Shares equal to the aggregate principal amount of such Notes, divided by C$0.5135, which is 80% of the volume-weighted average trading price of the Common Shares during the five trading days ending on June 29, 2023. On June 30, 2023, an aggregate of 24,342,740 Common Shares were issued to the June 2023 Noteholders in the June 2023 Exchanges. The June 2023 Exchanges were conducted as private placements, and the Common Shares were issued in reliance on the exemption from securities registration in Section 4(a)(2) under the Securities Act.
•
On December 9, 2022, the Company issued an aggregate of 8,692,128 Common Shares to certain shareholders (the “BioSteel Shareholders”) of BioSteel Sports Nutrition Inc. (“BioSteel”) in connection with certain call rights granted to the Company pursuant to the Unanimous Shareholders’ Agreement, dated as of October 1, 2019, by and among the Company, BioSteel and the BioSteel Shareholders party thereto, as amended, in exchange for the acquisition of approximately 12% of the outstanding shares of BioSteel. The Common Shares were issued to the BioSteel Shareholders in reliance on the exemption from securities registration in Section 4(a)(2) under the Securities Act.
•
On November 4, 2022, the Company, on behalf of Canopy USA, LLC (“Canopy USA”), issued 5,648,927 Common Shares to certain members of High Street Capital Partners, LLC (“HSCP”) as the first installment under the Third Amendment to Tax Receivable Agreement, dated October 24, 2022, by and among the Company, Canopy USA, Acreage Holdings America, Inc., HSCP and certain members of HSCP (the “TRA Amendment”); and on March 17, 2023, the Company, on behalf of Canopy USA, issued 7,102,081 Common Shares to certain members of HSCP as the second installment under the TRA Amendment, as consideration for the assignment of such holders’ rights under HSCP’s